Can oxidized LDL, vascular inflammation, and reduced endothelial nitric oxide reinforce one another and accelerate endothelial dysfunction and atherosclerosis?

The proposed interaction is biologically credible, particularly for endothelial dysfunction, but human evidence has not established the complete self-reinforcing cycle or its causal effect on atherosclerotic progression.

Clinical and observational evidence

• OxLDL is associated with impaired flow-mediated dilation (FMD), a measure largely reflecting nitric-oxide-dependent vasodilation. In a 10-year community cohort, higher circulating oxLDL predicted new carotid plaque independently of conventional LDL measures; other cohorts linked it to carotid IMT/plaque progression, although findings are inconsistent.
• Reduced NO signaling has comparatively direct human support for endothelial dysfunction: among 2,096 healthy young adults, higher ADMA—an endogenous nitric-oxide-synthase inhibitor—was independently associated with lower FMD. ADMA has also predicted carotid IMT progression and correlated with coronary calcium, but these are observational associations.
• Inflammatory markers have been inversely associated with FMD in the Framingham Offspring cohort, but conventional risk factors explained much of this association, and hs-CRP alone is an inconsistent indicator. hs-CRP ≥2 mg/L is a risk-enhancing factor when prevention decisions are uncertain, not a stand-alone vascular test.

Mechanistic basis

• OxLDL activates LOX-1/NF-κB signaling, ROS production, endothelial adhesion molecules, and leukocyte recruitment. It suppresses eNOS activity/expression and promotes ROS-mediated NO scavenging.
• ROS can oxidize BH4, uncouple eNOS, and shift the enzyme toward superoxide production, further reducing NO. Conversely, NO/NO donors inhibit LDL oxidation in cell-free, macrophage, and endothelial models; this effect may reverse under extreme oxidative conditions involving reactive nitrogen species.

Bottom line

• OxLDL, inflammation, and reduced endothelial NO are plausibly mutually reinforcing contributors to endothelial dysfunction and atherosclerosis, with strongest support for oxLDL-driven inflammatory/oxidative signaling and NO loss. The complete causal loop and its impact on human plaque progression remain unproven.